[heckel NEWSLETTER] 2024년 06월호

마케팅팀 2024.07.02 조회 753

heckel2024_06_DEGRO.jpg
1) DEGRO 2024 – 13.-15. June in Kassel: Presentation of thermography-controlled wIRA superficial hyperthermia

heckel shows the thermography-controlled wIRA superficial hyperthermia (hydrosun®TWH1500) at the 30th Congress of the German Society for Radiooncology (DEGRO) from 13th – 15th of June 2024 in Kassel – booth number K1 (near the poster area). We are looking forward to your visit!
Poster session P12 “Hyperthermie in der Radioonkologie und Radio-Immuntherapie” will take place on Friday, 14 Juni, 13:45 - 15:15.


heckel2024_06_ESHO2024.jpg

2024 Annual Meeting of ESHO – Abstract-Deadline: July 15th

The 2024 Annual Meeting of the European Society for Hyperthermic Oncology (ESHO) takes place from 06th – 8th November 2024 in Malaga/Spain Upcoming conferences.
Heckel is a Sponsor and Exhibitor. Users of fever-range whole-body hyperthermia as well as of wIRA superficial hyperthermia are welcome to submit abstracts!
The Abstract deadline is July 15th, 2024. 

heckel2024_06_Protocol-of-the-HISTOTHERM-study.jpg

Study protocol of HISTOTHERM – University Medical Center Freiburg
The study protocol of the recruiting prospective clinical trial HISTOTHERM – using thermography-controlled wIRA superficial hyperthermia with hydrosun®TWH1500 – has been published:
Thomsen A et al: Protocol of the HISTOTHERM study: assessing the response to hyperthermia and hypofractionated radiotherapy in recurrent breast cancer. Front Oncol. 2023 Dec 19;13:1275222. OPEN ACCESS https://pubmed.ncbi.nlm.nih.gov/38169879
 
Entry in the German Clinical Trial Register: https://drks.de/search/en/trial/DRKS00029221:
Included are “Patients with skin metastases or recurrent tumors from breast cancer, for whom neither surgery nor conventional fractionated radiotherapy is an appropriate or effective option.”
 
“Of interest here is not only the reaction of the tumor cells themselves, but also the reaction of the surrounding connective tissue, blood vessels and the immune system.”
 
“Before, during and after combination therapy of hyperthermia and low-fractionated radiotherapy, biopsies are taken and data on quality of life are collected by questionnaire. Therapy response is evaluated clinically and histologically.”
Please refer patients to this important clinical study (contact data in the drks-link).

heckel2024_06_STM2024.jpg
Successful Annual Meeting of American Society for Thermal Medicine (STM) in Houston

In May 2024 heckel along with the new American partner “heckel America” participated as sponsor and exhibitor in the Annual STM meeting in Houston. In lots of lectures and posters new findings in basic and clinical research were reported. Anne-Marie Lüchtenborg from University Medical Center Freiburg presented a case report on large-sized skin metastasis from ovarian cancer, successfully treated with wIRA superficial hyperthermia and hypofractionated radiotherapy.

heckel2024_06_SAHARA_trial.jpg

Swiss randomized study SAHARA on combined hyperthermia / radiotherapy in skin cancer

In Switzerland, the randomized controlled phase II trial Skin Cancer and Hyperthermia and Radiotherapy (SAHARA) has been registered and will soon recruit patients - https://clinicaltrials.gov/study/NCT06384053.
 
“The SAHARA Trial is investigating if adding hyperthermia to radiotherapy (RT) can enhance treatment outcomes by making cancer cells more sensitive to radiation, thus requiring lower doses and potentially reducing side effects. The trial compares high-dose RT alone with de-escalated RT plus hyperthermia. The aim is to demonstrate that the combination is non-inferior to standard RT in treating non-melanoma skin cancer (NMSC). The trial is designed for elderly people of 65 years or older.” Superficial hyperthermia is performed with hydrosun®TWH1500.
 
A Swiss standard RT protocol of 12 x 4 Gy (TD 48 Gy) is compared with 6 x 5 Gy (TD 30 Gy) + wIRA-hyperthermia directly before each RT-session.
All five Swiss users of hydrosun®TWH1500 participate in this study.


heckel2024_06_Front-Oncol.jpg
New Publication on “Innovative therapeutic strategies to overcome radioresistance in breast cancer”
Authors from Radiology Munich and Medical University Innsbruck published a comprehensive review and conclude that “the integration of nanotechnology, lncRNAs, miRNAs, signaling molecules, and hyperthermia presents a comprehensive strategy to combat radioresistance in breast cancer”. 
 
Arnold CR, Mangesius J, Portnaia I, Ganswindt U, Wolff HA. Innovative therapeutic strategies to overcome radioresistance in breast cancer. Front. Oncol. Vol. 14 – 2024. OPEN ACCESS
 
Radioology Munich has offered combined thermography-controlled superficial hyperthermia and radiotherapy since 2019: Hyperthermia - Therapy for greater tumor treatment success (radiologie-muenchen.de)

※본 게시물은 독일 heckel gmbH.에서 발행한 뉴스레터를 전달받아 발행한 것입니다.